Our lead novel cancer target: BGB001
BGB001 is a monoclonal antibody therapeutic against a novel receptor Tyrosin Kinase. This target is indicated in many metastatic cancers particularly ones with an EMT activity.
Oncology Focus
BerGenBio's CellSelect™ advanced technology platform is recognised as an important tool for oncology drug development partners. CellSelect™ has been developed to help researchers more fully understand the underlying causes of cancer and in turn develop completely new paradigms for its treatment.
With more than 3 million new cases and 1.7 million deaths in Europe each year according to WHO, cancer is the most important cause of death and morbidity in the region after cardiovascular diseases. Globally, the number of cancer mortalities are predicted to rise to over 11 million in 2030.
BerGenBio's unique expertise in cancer biology and its powerful technology platform can increase understanding of the underlying cause of cancers and increase the likelihood of success of drug candidates. Our platform can also help identify less effective compounds early on in the research and development pipeline saving time and effort.